Piers Ingram, Callio Therapeutics CEO
March 3, 2025 09:00 AM EST
Financing
Startups
Deals

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

Kyle LaHucik

Senior Reporter

Fra­zier Life Sci­ences and a cadre of well-known biotech in­vestors are com­ing to­geth­er for a new start­up in the an­ti­body-drug con­ju­gates field, an area of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times